for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biogen Inc

BIIB.OQ

Latest Trade

264.80USD

Change

-5.41(-2.00%)

Volume

352,790

Today's Range

264.42

 - 

269.64

52 Week Range

223.26

 - 

468.35

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Biogen Inc Posts Qtrly GAAP Diluted EPS $2.22

Oct 20 (Reuters) - Biogen Inc <BIIB.O>::THIRD QUARTER REVENUE $2,779 MILLION; GAAP DILUTED EPS $2.22; NON-GAAP DILUTED EPS $4.77.ROLLING SUBMISSION INITIATED FOR LECANEMAB (BAN2401) IN THE U.S. AND NEW DATA PRESENTED FOR ADUCANUMAB AND BIIB080 (TAU ASO).FINANCIAL GUIDANCE ASSUMES MINIMAL ADUHELM REVENUE IN 2021, RAMPING THEREAFTER.FY GUIDANCE ALSO CONTINUES TO ASSUME EROSION OF TECFIDERA AND RITUXAN IN THE U.S..SEES FY NON-GAAP DILUTED EPS $18.85 TO $19.35.ANNOUNCED PLANS TO SUBMIT U.S. NEW DRUG APPLICATION OF ZURANOLONE FOR DEPRESSION.SEES FY REVENUE $10.8 TO $10.9 BILLION.Q3 EARNINGS PER SHARE VIEW $4.09, REVENUE VIEW $2.67 BILLION -- REFINITIV IBES DATA.FY2021 EARNINGS PER SHARE VIEW $18.58, REVENUE VIEW $10.76 BILLION -- REFINITIV IBES DATA.SEES FY CAPEX $250 TO $300 MILLION.EXPECTS THE DECREASED REVENUE FROM HIGH MARGIN PRODUCTS TO REDUCE 2021 GROSS MARGIN PERCENTAGE COMPARED TO 2020.FY NONGAAP SG&A EXPENSE IS EXPECTED TO BE BETWEEN $2.6 BILLION AND $2.7 BILLION.QTRLY TECFIDERA REVENUE $498.6 MILLION VERSUS $953.1 MILLION.POTENTIAL UPTAKE OF ADUHELM IN THE U.S. IS DELAYED, BUT WE CONTINUE TO BELIEVE IN ITS LONG-TERM POTENTIAL.QTRLY ADUHELM REVENUE WAS $0.3 MILLION.QTRLY SPINRAZA REVENUE $444.1 MILLION VERSUS $494.4 MILLION.Further company coverage: <BIIB.O>. ((reuters.briefs@thomsonreuters.com;)).

Eisai Says Initiates Rolling Submission To U.S. FDA For Biologics License Application Of Lecanemab (Ban2401) For Early Alzheimer's Disease

Sept 27 (Reuters) - :EISAI INITIATES ROLLING SUBMISSION TO U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB (BAN2401) FOR EARLY ALZHEIMER'S DISEASE.EISAI - LECANEMAB CLARITY AD PHASE 3 CLINICAL TRIAL IN EARLY AD IS ONGOING & COMPLETED ENROLLMENT IN MARCH 2021 WITH 1,795 PATIENTS.EISAI - U.S. FDA HAS AGREED THAT RESULTS OF CLARITY AD, WHEN COMPLETED, CAN SERVE AS CONFIRMATORY STUDY TO VERIFY CLINICAL BENEFIT OF LECANEMAB.EISAI - LECANEMAB BLA BEING SUBMITTED UNDER ACCELERATED APPROVAL PATHWAY & BASED ON CLINICAL, BIOMARKER, SAFETY DATA FROM PHASE 2B CLINICAL TRIAL.EISAI - BLINDED SAFETY DATA FROM CLARITY AD WILL BE INCLUDED TO SUPPORT BLA OF LECANEMAB.

FDA Approves Samsung Bioepis And Biogen’s BYOOVIZ, LUCENTIS Biosimilar

Sept 20 (Reuters) - Biogen Inc <BIIB.O>::FDA APPROVES SAMSUNG BIOEPIS AND BIOGEN’S BYOOVIZ™ (SB11), LUCENTIS® BIOSIMILAR (RANIBIZUMAB-NUNA).

Biogen Reports Positive Topline Results From Phase 2 Convey Study In Small Fiber Neuropathy

Sept 16 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 CONVEY STUDY IN SMALL FIBER NEUROPATHY.BIOGEN - CONVEY STUDY 200 MG TWICE DAILY ARM MET PRIMARY ENDPOINT OF CHANGE FROM BASELINE TO WEEK 12 OF DOUBLE-BLIND PERIOD IN MEAN ADP SCORE.BIOGEN - WHILE 350 MG TWICE DAILY ARM DID NOT MEET PRIMARY ENDPOINT, IT MET STATISTICAL SIGNIFICANCE IN PGIC AT WEEK 12.BIOGEN INC - BOTH DOSES OF VIXOTRIGINE WERE GENERALLY WELL TOLERATED.BIOGEN INC - SAFETY PROFILE OF BOTH DOSES OF VIXOTRIGINE WAS CONSISTENT WITH PREVIOUS STUDIES OF VIXOTRIGINE WITH NO EVIDENCE OF ABUSE POTENTIAL.BIOGEN INC - 5.3% OF SUBJECTS DISCONTINUED OPEN-LABEL PART OF STUDY DUE TO ADVERSE EVENTS.BIOGEN INC - ACROSS ENTIRE STUDY MAJORITY OF AES WERE MILD OR MODERATE IN SEVERITY.BIOGEN INC - WILL FURTHER EVALUATE CONVEY DATA, PLANS TO COMPLETE PHASE 1 CLINICAL STUDY TO INFORM POTENTIAL NEXT STEPS IN DEVELOPMENT OF VIXOTRIGINE.

Berkshire Hathaway Dissolves Share Stake In Biogen and Axalta Coating Systems

Aug 16 (Reuters) - Berkshire Hathaway Inc::BERKSHIRE HATHAWAY DISSOLVES SHARE STAKE IN BIOGEN INC - SEC FILING.BERKSHIRE HATHAWAY DISSOLVES SHARE STAKE IN AXALTA COATING SYSTEMS LTD.BERKSHIRE HATHAWAY INC CUTS SHARE STAKE IN LIBERTY GLOBAL PLC BY 74.5% TO 1.9 MILLION CLASS C SHARES.BERKSHIRE HATHAWAY - CHANGE IN HOLDINGS ARE AS OF JUNE 30, 2021 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF MARCH 31, 2021.

Biogen Announces Results From Phase 3b NOVA Study Evaluating Every Six-Week Dosing With Natalizumab

Aug 2 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN ANNOUNCES RESULTS FROM PHASE 3B NOVA STUDY EVALUATING EVERY SIX-WEEK DOSING WITH NATALIZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS.BIOGEN - NEW ANALYSES FROM TOUCH PRESCRIBING PROGRAM SHOW AVERAGE 6-WEEK DOSING SCHEDULE ASSOCIATED WITH 88% REDUCTION IN PROBABILITY OF DEVELOPING PML.BIOGEN INC - NO STATISTICALLY SIGNIFICANT OR CLINICALLY MEANINGFUL DIFFERENCES IN SECONDARY ENDPOINTS AT WEEK 72 BETWEEN Q4W AND Q6W TREATMENT ARMS.BIOGEN INC - SAFETY FINDINGS IN NOVA STUDY WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF IV NATALIZUMAB.

Biogen, Eisai Announce Design Of Aduhelm Real-World Observational Phase 4 Study At AAIC 2021

July 29 (Reuters) - Eisai Co Ltd <4523.T>::BIOGEN AND EISAI ANNOUNCE DESIGN OF ADUHELM ICARE AD-US STUDY, THE FIRST REAL-WORLD OBSERVATIONAL PHASE 4 STUDY IN ALZHEIMER’S DISEASE AT AAIC 2021.BIOGEN INC - AIMS TO ENROLL AT LEAST 16 PERCENT LATINX AND BLACK/AFRICAN AMERICAN PATIENTS WITH ALZHEIMER'S DISEASE IN ICARE AD-US STUDY.BIOGEN INC - ICARE AD-US STUDY INTENDS TO ENROLL PATIENTS WITH ALZHEIMER'S DISEASE OVER FOUR YEARS FROM APPROXIMATELY 200 SITES IN U.S..

Biogen Sees FY2021 Non-GAAP Diluted EPS $17.50 To $19.00

July 22 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN REPORTS SECOND QUARTER 2021 RESULTS.QTRLY GAAP DILUTED EPS $2.99; NON-GAAP DILUTED EPS $5.68.BIOGEN - SECOND QUARTER REVENUE $2,775 MILLION.QTRLY ADUHELM™ REVENUE WAS $2 MILLION.BIOGEN - SEES FY 2021 TOTAL REVENUE $10.65 TO $10.85 BILLION.BIOGEN - SEES FY 2021 NON-GAAP DILUTED EPS $17.50 TO $19.00.QTRLY TECFIDERA REVENUE OF $487.6 MILLION VERSUS $1,181.6 MILLION REPORTED LAST YEAR.BIOGEN - 2021 NON-GAAP RESEARCH AND DEVELOPMENT EXPENSE IS EXPECTED TO BE BETWEEN $2.45 BILLION AND $2.55 BILLION.Q2 EARNINGS PER SHARE VIEW $4.54, REVENUE VIEW $2.60 BILLION -- REFINITIV IBES DATA.QTRLY SPINRAZA REVENUE OF $499.7 MILLION VERSUS $494.6 MILLION REPORTED LAST YEAR.FY2021 EARNINGS PER SHARE VIEW $18.61, REVENUE VIEW $10.64 BILLION -- REFINITIV IBES DATA.Further company coverage: <BIIB.O>. ((Reuters.Briefs@thomsonreuters.com;)).

Mirimus, Inc. Forms Strategic Collaboration With Biogen To Develop Rnai-Based Therapeutics For Neurological Disease Indications

July 21 (Reuters) - Biogen Inc <BIIB.O>::MIRIMUS, INC. FORMS STRATEGIC COLLABORATION WITH BIOGEN TO DEVELOP RNAI-BASED THERAPEUTICS FOR NEUROLOGICAL DISEASE INDICATIONS.MIRIMUS INC - TERMS OF COLLABORATION BETWEEN MIRIMUS AND BIOGEN ARE UNDISCLOSED.

Biogen, Innocare Announce License And Collaboration Agreement For Orelabrutinib

July 12 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN AND INNOCARE ANNOUNCE LICENSE AND COLLABORATION AGREEMENT FOR ORELABRUTINIB, AN INNOVATIVE CNS PENETRANT BTK INHIBITOR FOR THE POTENTIAL TREATMENT OF MULTIPLE SCLEROSIS.INNOCARE TO RECEIVE A $125 MILLION UPFRONT PAYMENT AND IS ELIGIBLE TO RECEIVE POTENTIAL DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS.BIOGEN WILL HAVE EXCLUSIVE RIGHTS TO ORELABRUTINIB IN FIELD OF MS WORLDWIDE AND CERTAIN AUTOIMMUNE DISEASES OUTSIDE OF CHINA.INNOCARE WILL RETAIN EXCLUSIVE WORLDWIDE RIGHTS TO ORELABRUTINIB IN FIELD OF ONCOLOGY AND CERTAIN AUTOIMMUNE DISEASES IN CHINA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up